Eric Richman - Sep 20, 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Sep 20, 2023
Transactions value $
$0
Form type
4
Date filed
9/22/2023, 04:34 PM
Previous filing
Sep 22, 2022
Next filing
Jun 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GANX Common Stock Options Exercise +54.9K +25.21% 273K Sep 20, 2023 Direct F1
holding GANX Common Stock 14.8K Sep 20, 2023 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Restricted Stock Units Options Exercise $0 -54.9K -100% $0.00* 0 Sep 20, 2023 Common Stock 54.9K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 Shares are held by the Eric I. Richman Living Trust (the "Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of his proportionate pecuniary iinterest therein.
F3 The RSUs vested fully on September 20, 2023.